Clinical trials: Metastatic Neoplasm
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Phase 2, Zanzalintinib
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS
- Conditions
- Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic
- Trial name
- NCT07283731
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Metastases, Colorectal Cancer
Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer
The primary objective of this study is to correlate the percentage change in apparent diffusion coefficient (ADC) between baseline and early therapy (at day 14) with tumor regression grade (TRG) measured in the surgical resection…
- Trial name
- NCT02355353
- Testing
- Experimental: imaging arm
- Volunteers
- 31 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC (Advanced Non-small Cell Lung Cancer)
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype…
- Trial name
- NCT07718737
- Testing
- AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)
- Where
- 7 sites in United States, Australia
- Volunteers
- 512 people
- Sponsor
- Multitude Therapeutics Inc.
Metastatic Prostatic Adenocarcinoma
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.
- Trial name
- NCT03069937
- Testing
- Docetaxel, Degarelix
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Medical University of South Carolina
Hepatocellular Carcinoma, Circulating Tumor Cell
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform
This study aims to isolate CTCs in peripheral venous blood of liver cancer patients by inertial focusing principle-based microfluidic device, determine the relationship between the number of CTCs and patient prognosis and…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Whole Genome Sequencing
- Trial name
- NCT05242237
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Non Small Cell Lung Cancer, BRAF V600 Mutation
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
BLaDE cohort will evaluate overall survival (OS), real world progression-free survival (PFS), best response and duration of treatment in patients with advanced, metastatic Non-Small Cell Lung Cancer (NSCLC) harboring BRAF V600E…
- Trial name
- BLaDE (NCT04775095)
- Where
- 2 sites in France
- Volunteers
- 163 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Cutaneous Metastatic Melanoma
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
The investigators aim to include 100 local participants over the next 5 years in a two-stage sequential randomized interventional study of intralesional Interleukin-2 (IL-2) and Bacillus Calmette Guerin (BCG) to assess the…
- Trial name
- NCT03928275
- Testing
- Interleukin-2, Combination therapy Interleukin-2 and Bacillus Calmette Guerin
- Sponsor
- Carman Giacomantonio
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Neoplasms
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic…
- Trial name
- NCT02410512
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 610 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
This study evaluates Navtemadlin (KRT-232) in combination with Pembrolizumab as a maintenance therapy in patients with locally advanced and metastatic non small cell lung cancer.
- Trial name
- NCT05705466
- Testing
- Navtemadlin, Pembrolizumab
- Sponsor
- Kartos Therapeutics, Inc.
Lung Cancer
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for…
- Trial name
- NCT00006229
- Testing
- carboplatin, paclitaxel, rebimastat
- Where
- 69 sites in United States, Austria and 12 more
- Volunteers
- 774 people
- Sponsor
- NCIC Clinical Trials Group
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of dasatinib when given together with cytarabine and idarubicin hydrochloride and to see how well they work in treating patients with acute myeloid leukemia that is…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01876953
- Testing
- cytarabine, idarubicin, dasatinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD…
- Trial name
- NCT00215995
- Testing
- Cisplatin, Irinotecan, ZD 1839
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
- Trial name
- NCT00186277
- Testing
- Oxaliplatin, Taxotere
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Pancreatic Neoplasms, Neoplasm Metastasis
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
The study explores the efficacy and safety of oxaliplatin combined with irinotecan liposome injection II via hepatic arterial infusion (HAIC) followed by sequential treatment with 5-FU/LV (HAIC) or oral administration of S-1 in…
- Conditions
- Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer
- Trial name
- NCT06538623
- Testing
- Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin, Tegodor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study.
- Conditions
- Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
- Trial name
- NCT06278454
- Testing
- NRT6008 Injection + Systematic chemotherapy
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Stage IV Gastric Cancer With Metastasis
Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study
The purpose of this study was to evaluate the efficacy of camrelizumab combined with nab-paclitaxel intraperitoneal infusion, intravenous chemotherapy and S-1 in the treatment of advanced gastric cancer with peritoneal…
- Trial name
- NCT05441254
- Testing
- Camrelizumab; Nab-paclitaxel; S-1
- Volunteers
- 33 people
- Sponsor
- Zhongshan Hospital Xiamen University
Cancer of the Head and Neck
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
- Trial name
- NCT04470024
- Testing
- INCAGN01876, INCMGA00012, DPV-001
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Providence Health & Services
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.